 Kiniksa Pharmaceuticals NASDAQ:KNSA was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a 23.00 target price on the stock. Zacks Investment Researchs target price suggests a potential upside of 15.12 from the stocks previous close. According to ... 